We have recently published the following paper based on our collaborative effort on imaging and clinical aspects of MERS-CoV (middle east respiratory syndrome c.virus).
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) was identified in 2012 as the causative agent of a severe, lethal respiratory disease occurring across several countries in the Middle East. To date there have been over 1600 laboratory confirmed cases of MERS-CoV in 26 countries with a case fatality rate of 36%. Given the endemic region, it is possible that MERS-CoV could spread during the annual Hajj pilgrimage, necessitating countermeasure development. In this report, we describe the clinical and radiographic changes of rhesus monkeys following infection with 5 106 PFU MERS-CoV Jordan-n3/2012. Two groups of NHPs were treated with either a human anti-MERS monoclonal antibody 3B11-N or E410-N, an anti-HIV antibody. MERS-CoV Jordan-n3/2012 infection resulted in quantifiable changes by computed tomography, but limited other clinical signs of disease. 3B11-N treated subjects developed significantly reduced lung pathology when compared to infected, untreated subjects, indicating that this antibody may be a suitable MERS-CoV treatment.
Reed F. Johnson , Ulas Bagci , Lauren Keith , Xianchun Tang , Daniel J. Mollura , Larry Zeitlin , Jing Qin , Louis Huzella , Christopher J. Bartos , Natasha Bohorova , Ognian Bohorov , Charles Goodman , Do H. Kim , Michael H. Paulty , Jesus Velasco , Kevin J. Whaley , Joshua C. Johnson , James Pettitt , Britini L. Ork , Jeffrey Solomon , Nicholas Oberlander Quan Zhu , Jiusong Sun, Michael R. Holbrook , Gene G. Olinger, Ralph S. Baric, Lisa E. Hensley, Peter B. Jahrling , Wayne A. Marasco
LINK TO THE PAPER: http://www.cs.ucf.edu/~bagci/publications/virology16.pdf